Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Samantha N Reiss"'
Publikováno v:
CNS Oncology, Vol 7, Iss 3 (2018)
Aim: To establish the safety and feasibility of rapidly infusing rituximab over 90 min in patients with primary CNS lymphoma (PCNSL). Patients & methods: We retrospectively reviewed all patients with PCNSL who received rapid rituximab infusions (RRI)
Externí odkaz:
https://doaj.org/article/72563202a4244fd8b4ba0c25bb26fbdf
Autor:
Mustafa S. Ascha, Alemseged A. Asfaw, Prakirthi Yerram, Samantha N. Reiss, Sarah D. Brake, Niquelle B. Wadé
Publikováno v:
Cancer Research. 83:P1-07
Introduction: Comorbid conditions can significantly impact various aspects of cancer care and therefore are often utilized as covariates to control for selection bias in observational studies. Oncology based electronic health record (EHR) data is oft
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::24742d7cfb4bdfc5cd85b294acb4a602
https://doi.org/10.1158/1538-7445.sabcs22-p1-07-04
https://doi.org/10.1158/1538-7445.sabcs22-p1-07-04
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-7 (2017)
Abstract Background Programmed cell death ligand-1 (PD-L1) expression has been reported in up to 61% of high grade gliomas (HGG). The purpose of this study was to describe safety and efficacy of PD-1 inhibition in patients with refractory HGGs. Metho
Externí odkaz:
https://doaj.org/article/54d185b0a2d34cfbba288d7a427041ee
Publikováno v:
Leuk Lymphoma
Relapsed/refractory Primary Central Nervous System Lymphoma (R/R PCNSL) has a poor prognosis with no established preferred treatment. We report the efficacy and toxicity of a combination chemotherapy regimen: methotrexate, carmustine, etoposide, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c6e879089508717f226b3c1af2df4cf
https://doi.org/10.1080/10428194.2021.1998481
https://doi.org/10.1080/10428194.2021.1998481
Autor:
Prakirthi Yerram, Samantha N. Reiss, Lisa Modelevsky, Lauren Schaff, Anne S. Reiner, Katherine S. Panageas, Christian Grommes
Publikováno v:
Annals of Lymphoma. 7:1-1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9865f637829efa54420956d126008886
https://doi.org/10.21037/aol-22-19
https://doi.org/10.21037/aol-22-19
Publikováno v:
J Neurooncol
PURPOSE: An increased incidence in hematologic toxicity has been reported with the addition of bevacizumab to lomustine for patients with recurrent or progressive high grade gliomas (HGG). Data regarding incidence of toxicity with combination bevaciz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc8f8f390b3c45a91b5b2ab357216ea1
https://doi.org/10.1007/s11060-019-03266-0
https://doi.org/10.1007/s11060-019-03266-0
Autor:
Krisoula Spatz, Prakirthi Yerram, Lauren DeRespiris, Richard F Tizon, Terry K. Pak, Andréa LeVoir, Scott Freeswick, Samantha N Reiss, Lisa Modelevsky, Josiah D. Land, Sherry Mathew, Carmen Lau, Shirley Qiong Yan, Lauren Koranteng, Phuong H. Dao, Kate E Reichert, Jennifer Thackray, Nicole P Daukshus, Jennifer S. Orozco, Stephen Harnicar, Larry W Buie, Manpreet K. Boparai, Michael J Buege, Dazhi Liu
Publikováno v:
J Oncol Pharm Pract
PurposeWith the rapid spread of COVID-19 in New York City since early March 2020, innovative measures were needed for clinical pharmacy specialists to provide direct clinical care safely to cancer patients. Allocating the workforce was necessary to m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f2232d99ac821194bf5e6eebc3d4856
https://pubmed.ncbi.nlm.nih.gov/33459159
https://pubmed.ncbi.nlm.nih.gov/33459159
Autor:
Samantha N Reiss, Lisa Modelevsky, Thomas Kaley, Richard F Tizon, Rachel Garonce, Marcel Smith
Publikováno v:
CNS Oncology
Aim: To establish the safety and feasibility of rapidly infusing rituximab over 90 min in patients with primary CNS lymphoma (PCNSL). Patients & methods: We retrospectively reviewed all patients with PCNSL who received rapid rituximab infusions (RRI)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80e769c9e3aee8d27ba07292c28e1536
https://pubmed.ncbi.nlm.nih.gov/30221993
https://pubmed.ncbi.nlm.nih.gov/30221993
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-7 (2017)
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-7 (2017)
Background Programmed cell death ligand-1 (PD-L1) expression has been reported in up to 61% of high grade gliomas (HGG). The purpose of this study was to describe safety and efficacy of PD-1 inhibition in patients with refractory HGGs. Methods This I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71831a11166c0ec5e028502275f371ca
https://doi.org/10.1186/s40425-017-0302-x
https://doi.org/10.1186/s40425-017-0302-x
Autor:
Ekaterina Kachur, Larry W Buie, Anne S. Reiner, Samantha N Reiss, Josiah D. Land, Elena Pentsova, Gregory J. Riely, Katherine S. Panageas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79a27857047758c96863fd6a95120ed9
https://europepmc.org/articles/PMC5692203/
https://europepmc.org/articles/PMC5692203/
